Becker's Life Sciences E-Newsletter

To sign up for Becker's Life Sciences E-Newsletter or any of our other E-Newsletters, click here.

If you are experiencing difficulty receiving our newsletters, you may need to whitelist our new domain. Please visit https://www.beckershospitalreview.com/not-receiving-our-newsletters-check-this-guide.html for more information.

Archived Becker's Life Sciences E-Newsletters

December 18, 2024

• Drug company to cut 65% of staff | Flu, COVID vaccines get fast-track status | Study links Ozempic to vision loss | FDA recalls 230K bottles of antidepressant

December 11, 2024

• Zepbound beats out Wegovy in study | The race to create an oral GLP-1 drug | Walgreens eyes private equity sale | 20 drugs now in shortage

December 04, 2024

• Ozempic is getting cheaper | Sanofi adds $600M plant | 6 GLP-1 study findings to know | Forbes honors '30 Under 30' in healthcare

November 27, 2024

• Controversial drug trial halted | RFK on Ozempic | 1st gene therapy delivered into brain approved | Biden proposes Medicare coverage for weight loss drugs

November 20, 2024

• Mounjaro lowers diabetes risk | FDA rejects liver disease drug | 53% of adults are eligible for Ozempic | Trump taps Dr. Oz for CMS lead

November 13, 2024

• COVID-Flu vaccine trial advances | Warning added to Ozempic, Mounjaro labels | FDA could pull decongestant | UnitedHealth sued over Amedisys deal

November 06, 2024

• Trump wins election: 7 notes | Ozempic, Wegovy shortages fixes | Patient dies in gene-therapy trial | US drugmakers to cut reliance on China

October 30, 2024

• Trump, Harris on drug prices | FDA recalls antidepressant bottles | Alzheimer's drug trials raise ethical concerns | 9 drugs in shortage

October 23, 2024

• FDA rethinks Mounjaro shortage | Flu-COVID drug study paused | CVS workers go on strike | Walmart starts prescription deliveries

October 16, 2024

• FDA reconsiders Mounjaro ban | 1st COVID-flu combo test approved | GSK settles lawsuits fo $2.2B | Walgreens to close 1,200 stores

October 09, 2024

• Eli Lilly spends $4.5B on new facility | Execs charged in $1.3B drug scheme | CVS to lay off 632 | CMS tweaks drug price negotiations

October 02, 2024

• Patients sue Novo Nordisk, Eli Lilly | Drugmaker, execs pay $40M settlement | Pfizer pulls sickle cell drug | 8 drugs in shortage

September 25, 2024

• Inside the GLP-1 'price war' | FDA approves 1st self-administered flu vaccine | 10 common drugs in shortage | Harris' drug spending cap plan: 4 things to know

September 18, 2024

• GLP-1 drugs in the works | Wegovy beats rival in trial | Walgreens to pay $106M over fraud allegations | Ozempic generics could cost 90% less

September 11, 2024

• Eli Lilly value could hit $1T | AbbVie sues BeiGene over trade secret theft | AstraZeneca cancer drug fails trial | Trump-Harris debate: 3 healthcare takeaways

September 04, 2024

• Sandoz plans Ozempic generic US launch | Healthcare execs accused of lying to Congress | 6 drugs now in shortage | 10 healthcare industry lawsuits, settlements

August 28, 2024

• Pfizer goes direct to consumer | FDA clears new COVID shots | 4 updates on Mounjaro, Ozempic | CDC's outlook for 2024-25 virus season

August 21, 2024

• Eli Lilly takes action against copycats | Lyoks to lay off 75% of workforce | Patients tamper with Ozempic, Mounjaro | Walgreens inks $100M clinical trial deal

August 14, 2024

• FDA calls out Bristol Myers | How 4 GLP-1 makers fared in Q2 | Medicare drug price negotiations: 10 notes | The GLP-1 questions facing health systems

August 7, 2024

• FDA OKs 1st gene therapy for synovial sarcoma | VP picks' stance on pharmaceutical costs | 42% of online semaglutide sellers are illegal | Drug combo could boost cancer treatment efficacy

July 31, 2024

• Obesity pill trial earns drugmaker $16B | US drugmaker on verge of closure | 4 notes on fall COVID vaccines | Could Amazon be headed for big healthcare losses?

July 24, 2024

• The state of drug shortages | The 'best' weight loss drug remains elusive | Endo recalls mislabeled drug lot | 10 top execs that have left Optum

July 17, 2024

• Faux-zempic' market on the rise | Rite Aid hit with security breach | Cancer drug shortage: 8 updates | JD Vance's healthcare record: 7 things to know

July 10, 2024

• Ozempic v. Mounjaro: Which came out on top | Eli Lilly plans $3B acquisition | PBMs dominate drug pricing: FTC | Insurers grab $50B from 'questionable' MA coding

July 03, 2024

• Chevron ruling could stall news drugs | Biden tells Ozempic maker to 'Stop ripping off' Americans | FTC probes Teva | Moderna snags $176M for flu shot development

June 26, 2024

• Eli Lilly sues phony drugmakers | Teva launches 1st generic GLP-1 | J&J buys biologics company for $850M | 5 drugs now in shortage

June 12, 2024

• Novo Nordisk under Senate scrutiny | Bristol Myers Squibb to lay off 860+ | FDA panel passes potential Alzheimer's drug | Bill takes aim at healthcare 'corporate greed'

June 5, 2024

• Novartis sues Maryland over 340B law | Sagent recalls 2 lots of cancer drug | Novo Nordisk races to boost Ozempic, Wegovy production | Fortune 500's top 25 healthcare cos.

May 29, 2024

• Pfizer recalls 5 drug lots | J&J to buy skin drug for $1.25B | 10 drugs in shortage | Eli Lilly commits $5.3B to more Zepbound, Mounjaro production | 12 health systems moving to Epic

May 22, 2024

• AstraZeneca to pay $107.5M for drug patent infringement | FDA approves 2 Eylea biosimilars | 10 highest-paid healthcare CEOs | GSK sees wins in asthma drug trials | 15 top health systems: Fortune

May 16, 2024

• Nearly 200 exposed to measles at UC Davis Health | Merck halts research on skin cancer combo drug | Intermountain expands central lab | GLP-1s: 8 notes | Ascension confirms ransomware attack

May 8, 2024

• Pfizer halts study after child dies | Cue Health lays off 49% of workforce | Emergent BioSolutions to close 2 sites, start layoffs | Steward to sell all 31 hospitals | FTC wants details of Novo's $16.5B deal

May 1, 2024

• J&J to resolve most cancer talc claims for $6.5B | Walmart Health shutters | FDA approves Pfizer's 1st gene therapy | 25 most expensive hospital drugs | 11 drugs in shortage

April 24, 2024

• 25 most popular drugs | Hospitals slam FTC's noncompete ban | Lawmakers probe Novo Nordisk | Eli Lilly scoops injectable manufacturing site from Nexus | 4 Ozempic updates

April 17, 2024

• Drug shortages hit 23-year high | Pfizer to lay off 119 | Biotech CEO sentenced for $28M fraud scheme | HCA, CHS, Tenet and UHS exec pay

April 10, 2024

• Drugmaker files for bankruptcy | A potential Ozempic baby boom | 2nd ransomware group targets Change | Zepbound now in shortage | Amylyx to pull ALS therapy from market

April 3, 2024

• The $5 Ozempic debate | 3 drugmakers announce recalls | 10 drugs now in shortage | 35 billionaires in US healthcare | Verily cuts jobs

March 27, 2024

• The $4.25M drug | Wegovy sidesteps 'forever drug' problem | A new COVID-19 drug | Novo Nordisk to buy drugmaker for $1.1B | FDA rejects cancer drug candidate

March 20, 2024

• GSK, Duke halt RSV shot trial | Eli Lilly, Amazon partner on weight loss drug delivery | AstraZeneca to acquire Fusion Pharmaceuticals in $2.4B deal | 9 drugs now in shortage

March 13, 2024

• FDA delays decision on Eli Lilly Alzheimer's drug | Amylyx may pull ALS drug | Syphilis drug shortage may end in Q4 | Wegovy secures 2nd indication | 9 Ozempic updates

March 6, 2024

• Mark Cuban dives into drug manufacturing | Drugmakers send CMS counteroffers in fair price negotiations | 8 Ozempic updates | 1st OTC glucose monitor cleared | FDA revokes approval of Pepaxto

February 28, 2024

• Weight loss drug candidate could rival Ozempic | State board sets a drug price ceiling | NY asks FDA to address Singulair controversy | Amgen builds $474M facility | 2 drugs nearing approval to know

February 21, 2024

• Drugmakers struggle to gain traction for gene therapies | AbbVie CEO to step down | FDA places clinical holds on 2 drug studies | 1st T cell melanoma drug approved | 10 drugs now in shortage

February 14, 2024

• Gilead scoops drugmaker for $4.3B | 6 Ozempic updates | UT Southwestern, Pfizer partner | 55 best hospitals to work for: Forbes | FDA clears metastatic pancreatic cancer drug

February 7, 2024

• Biogen pulls Aduhelm | Amazon cuts healthcare jobs | 2 cancer drug injectables go into shortage | 5 Ozempic updates | 6 cancer vaccines showing promise

January 31, 2024

• Paxlovid emergency use to end | Drugmakers look to class of cancer drugs for growth | Contaminated medical products tied to cases of early Alzheimer's | Gene therapy allows boy to hear | 9 drugs now in shortage

January 24, 2024

• FDA finds deficiencies at Eli Lilly plant | Ozempic, Mounjaro get pricier | Drug cost trends in 2024 are 'nearly unprecedented' | Best, worst states to retire | FDA clears CRISPR therapy for 2nd disease

January 17, 2024

• Drugmaker halts study after 2 unrelated deaths | Developing a staph vaccine when 'the rules are different' | Eli Lilly weight-loss drug platform draws concern | 5 new drug shortages

January 10, 2024

• J&J to buy Ambrx for $2B | Eli Lilly to sell weight loss drugs directly to consumers | Pfizer to lay off 285 in NY | Best healthcare jobs in 2024 | 4 Ozempic updates

January 3, 2024

• Goldman Sachs closes on $650M life sciences investment fund | Bristol Myers to buy cancer therapy co. for $4B | FDA warns of infection risk over fake Ozempic | Verily's CMO steps down

December 20, 2023

• CareFirst sues J&J | Biotech co. lays off 15% of staff | AstraZeneca to buy vaccine co. for $1.1B | Bristol Myers scraps cancer drug trial | 13 of 20 most popular drugs in shortage

December 13, 2023

• Biotech CEO pleads guilty to fraud scheme | US' 1st CRISPR gene therapy to treat sickle cell approved | Moderna exec steps down | Eli Lilly obesity drug hits shelves | Pfizer donates rights to cancer drug

December 06, 2023

• 3 patients die in drug trial | Intermountain's biotech spinoff snags $10M | Pfizer exits BIO | The Mark Cuban effect on drug pricing | Eli Lilly blood cancer drug gains approval

November 29, 2023

• Eli Lilly opens space for healthcare startups | 3 biotech co. layoffs | AstraZeneca dives into digital health | Exela Pharma recalls 400K drugs | 1st desmoid tumor drug approved

November 22, 2023

• Timber Pharmaceuticals files for bankruptcy | Surgeons raise concerns about Ozempic | FDA finalizes tougher rules for consumer drug ads | 6 drugs now in shortage

November 15, 2023

• Thermo Fisher Scientific to close Ala. plant, lay off 97 workers | Wegovy cuts risk of major heart events: Study | What 5 hospitals pay their Epic talent | 1st Chikungunya virus vaccine approved

November 08, 2023

• Sangamo Therapeutics cuts 40% of workforce | Cancer drug trial on hold | Amazon launches One Medical for Prime | FDA probes hospitalizations tied to fake Ozempic | Drug study sees 'unprecedented' results

November 01, 2023

• Professor's Alzheimer's drug research paused amid investigation | Pfizer to close NJ site, relocate nearly 800 workers | CVS, Walgreens walkouts may include 4,500 | Danaher taps biotech exec

October 25, 2023

• Drugmaker to lay off 100+ post Biogen acquisition | Roche to buy drugmaker from Pfizer, Roivant for $7B | Moderna partners with Caris Life Science | J&J dengue pill shows promise | AI drugs' hype wears off

October 18, 2023

• Alzheimer's drug researcher accused of 'egregious misconduct' | Investment firm buys minority stake in Catalio | Walgreens, CVS workers plan strike | Paxlovid popularity dwindles

October 11, 2023

• Bristol Myers Squibb to buy cancer drugmaker for $5.8B | Sana Biotechnology cuts 29% of workforce | Cancer drug study partially halted after patient death | Moderna to develop combo flu, COVID-19 shot

October 04, 2023

• 31 drugmakers, biotechs form pro-M&A group | AstraZeneca settles drug lawsuits for $425M | Biogen shutters digital health unit | The wealthiest people in healthcare | Apellis recalls 61K injection needles

September 27, 2023

• EPfizer, Ginkgo ink $331M deal | Weight-loss drug market may hit $100B by 2035 | 58 best healthcare employers, per US News | Penn Medicine tests Lyme disease vaccine | Ulcer drug recalled

September 20, 2023

• Eli Lilly sues spas, clinics over Mounjaro copycat | 3 biotech co. layoffs | J&J rebrands, cuts script logo | How Ascension is paring down amid $3B loss | Ozempic, Wegovy shortages could last years

September 13, 2023

• 2seventy bio cuts 40% of workforce | Ozempic, Wegovy tested as dementia, addiction drug | Aktiv Pharma Group to shutter operations | The healthcare quality blindspot | 5 updates on Mark Cuban's drug co.

September 06, 2023

• Absci lays off 15% of staff | Walgreens CEO steps down | Drugmaker recalls heart drug after dose mix-up | When C-level roles are too big for one person | 1st drug reduces 'sticky' cholesterol by 65%

August 30, 2023

• CVS launches biosimilar subsidiary | Pfizer eyes reopening NC plant | Fla. hospitals prep for Idalia | Rite Aid to file for bankruptcy | QuantHealth raises $15M | HHS invest $1.4B in new COVID-19 tools

August 23, 2023

• FDA halts Gilead cancer drug study | Willow taps new biopharma partner | Optum lays off nurses | 10 drugs CMS might tap for negotiations | FDA warns AstraZeneca over false advertising of COPD drug

August 16, 2023

• FDA halts drug trial after subject's death | Drug co. cuts COO role, to lay off 400 | Top 10 universities for life sciences | Healthcare's widest CEO-worker pay gaps | Novo Nordisk to buy obesity drugmaker for $1B

August 09, 2023

• Ozempic, Mounjaro stomach paralysis claims led to lawsuit | Amazon zeros in on genomics | Ill. system lays off 20% of leaders | Sage considers job cuts, drug pricing delays

August 02, 2023

• Biogen to spend $7.3B on rare disease drugmaker | CVS Health to cut 5,000 jobs | FDA approves GSK cancer drug | Mich. hospital to close | Pfizer laying off 69 in Ill.

July 26, 2023

• Biogen to cut 1,000 jobs | Drug shortages may worsen after tornado hit Pfizer plant | Cancer drug shortages threaten clinical trials | CHS to sell 3 hospitals | 5 Ozempic updates

July 19, 2023

• Eli Lilly to spend $1.93B on weight loss drugmaker | J&J must pay $19M to cancer patient | Mayo Clinic taps biotech innovation hub leaders | Cost Plus Drugs could hit hospitals by fall | Nurses protest name of Mo. hospital

July 12, 2023

• Illumina hit with $476M fine for Grail acquisition | CVS-owned pharma co. to cut 195 workers | Amazon discounts healthcare on Prime Day | Drug trial paused after 7 patient deaths | 138 drugs in shortage

July 05, 2023

• Ex-Pfizer worker faces insider training charges | FDA rejects Amneal's Parkinson's drug | Trial for 1st fully AI-generated drug underway | 42 hospitals cutting back care | 1st hemophilia gene therapy approved

June 28, 2023

• Eli Lilly drug brings 24% weight loss | 7 drugs in shortage | New COVID-19 variant on CDC's radar | Pfizer ends weight loss drug trial | UPMC to help build R&D facility

June 21, 2023

• Eli Lilly to acquire Dice Therapeutics in $2.4B deal | 5 deaths partially halt drug trial | Kan. hospital fires CEO | Why drug shortages might worsen | Biden taps leader of CDC

June 14, 2023

• Pfizer running out of penicillin | Illumina CEO resigns | HHS adds 25 drugs to rebate list | Calif. hospital to lay off 100+ | 116 women in health IT to know | Beaconcure raises $14M

June 7, 2023

• Merck sues CMS over drug price negotiations | What's in GV's portfolio? | Mark Cuban to sell Humira biosimilar | Pa. system pulls out of US News ranking | Trinity Life Sciences taps new CEO

May 31, 2023

• Oncologists ration cancer drugs amid shortage | J&J taps Ceramedix for new resident co. | PTC Therapeutics to lay off 94 | Amazon eyes medical affairs lead | Ascension posts $1.4B operating loss

May 24, 2023

• Athenex to close July 1 | Walgreens 'full steam ahead' on clinical trials | California hospital to file for bankruptcy | Moderna buys Mass. biomanufacturing plant | Healthcare's highest-paid CEOs

May 17, 2023

• CVS to shutter clinical trials business | FTC sues to block $28M Amgen-Horizon deal | Syneos Health to be acquired for $7.1B | Eli Lilly must pay $183M+ for violating False Claims Act | The healthiest county in each state

May 10, 2023

• FDA finds deficiencies at Eli Lilly plant | 1st RSV vaccine gains approval | Novavax to cut 25% of workforce | 5 gene therapy candidates to watch | Penn Med physicians vote to unionize

May 03, 2023

• Cepheid to lay off 600+ | Who's paying for gene therapies? | HHS to end COVID-19 vaccine rule | Biopharma investors target oncology, immunology | Police shoot woman in Ga. ER

April 26, 2023

• Cedars-Sinai could secure millions from $10.8B biotech deal | Mark Cuban hasn't 'f—ed up' the pharma industry yet | Eli Lilly starts new Mounjaro clinical trial | 13 execs resign | Moderna, IBM explore AI's healthcare potential

April 19, 2023

• Emerald Cloud Labs cuts jobs, shuts down offices | mRNA shot sparks 'big shift' in cancer vaccine development | Exec pay at Tenet, HCA, CHS | Horizon Therapeutics made $3B in '22, hasn't licensed a drug in 15 years

April 12, 2023

• Cleveland Clinic, University Hospitals take over biotech co. incubator | Why California can't walk away from Walgreens | Mark Cuban's pharmacy picks up J&J brand-name drug | 35 billionaires in US healthcare

April 05, 2023

• Cancer drug trial halted after 2 deaths | J&J scraps RSV vaccine plans | 14 drug shortages worsen amid Akorn closure | New COVID variant in 18 states | 10 healthiest, unhealthiest cities

March 29, 2023

• Roche's biotech co. lays off 265 | CVS Health closes Signify acquisition | 4 drugs discontinued amid Akorn closure | Life sciences investment firm raises $600M | Razor-thin hospital margins are the new normal

March 22, 2023

• Cancer drug trial halted after patient death | Intermountain launches biotech co. | 150 top places to work in healthcare | Pfizer leads $123M financing round for biotech co. | Mo. health system cuts leadership roles

March 15, 2023

• US sues Rite Aid | Pfizer to acquire Seagen for $43B | Penn Med cuts jobs | Calif.'s 1st all-electric life sciences facility lands $310M loan | Top 83 hospitals for patients: Healthgrades

March 08, 2023

• Mark Cuban's 1st step into brand-name drug market | 'We're done': Calif. cuts ties with Walgreens | Moderna may test bird flu, mpox vaccines in 2023 | Life sciences co. taps former Dell, IBM leader for CEO

March 01, 2023

• Eli Lilly caps insulin costs | Mark Cuban's pharmacy sees 2 million customers | How 5 drugmakers fared in 2022 | Sequoia acquires biotech co. | Hospital margins aren't seeing relief

February 22, 2023

• Mark Cuban seeks independent pharmacists | Amazon acquires One Medical for $3.9B | Fujifilm Irvine Scientific sued over recalled embryo culture oil | How AI can speed up drug development | 7 US healthcare billionaires

February 15, 2023

• HHS unveils 3 new drug price models | Walmart, drugmakers face eye drop suits | Northwell exec weighs in on NY masking requirements | Va. invests $67M in biotech | 11 cities hit hardest by inflation

February 08, 2023

• Teva exits PhRMA | CVS, Oak Street strike $10.6B deal | Former Google CEO to serve on federal biotech commission | State of the Union: 10 healthcare notes | Pharmacist among those arrested in $1.5M pill mill case

February 01, 2023

• Humira's 1st biosimilar enters market | PHE to end May 11 | Pfizer invests $25M in biotech co. | Nurses asked to give up licenses amid fake degree scheme | $290M life sciences facility gets green light

January 25, 2023

• Amazon kicks off monthly script service | Kroger's 1st personalized medicine trial | Digital life sciences VC fund launches with $350M | Meet Mark Cuban's 3 PBM partners | 20 systems spending the most on contract labor

January 18, 2023

• Drug researcher gets 3 years in prison for asthma drug study lie | Heparin shortage drags on | Cleveland Clinic expects $200M loss | Biotech investment to bounce back | Top 50 hospitals: Healthgrades

January 11, 2023

• Life science investors to ramp up M&A activity | 3rd Alzheimer's drug approved | Healthcare at its worst: 10 Shkreli awardees | 5 J&J investments | Sexual assault claims spur Cleveland Clinic probe

January 04, 2023

• House blames FDA, Biogen for Aduhelm fail | Biotech investments slowed in 2022 | 2 biotech CEOs charged in alleged fraud | Viatris acquires 2 life sciences cos. | Strike set at NYC hospitals

December 21, 2022

• Can health systems compete with CVS, Walgreens? | AbbVie exits 2 pharma lobbies | $1.7T omnibus bill: 8 healthcare takeaways | Labcorp opens LA lab | HHS unlocks Tamiflu

December 14, 2022

• Amgen snags Horizon in $27.8B deal | Top 10 pharma cos. by revenue | Inmate shot, killed in Texas hospital | Syndax issues $150M public offering pricing | Flu activity by state

December 07, 2022

• CVS, Walgreens, Walmart appeal Ohio $650M opioid ruling | J&J Innovation backs biotech co.'s $60.75M funding round | Seattle's next life sciences building | 50 states ranked by health

November 30, 2022

• Drugmaker cuts 75% of R&D workforce | Tamiflu demand jumps 100% | Fired CEO sues MetroHealth | 2nd participant in Eisai's Alzheimer's drug trial dies | Children's Hospital of Philadelphia deploys Amazon genomics service

November 23, 2022

• Pharma giants ditch Twitter | FDA OK's 1st drug to delay Type 1 diabetes onset | Merck makes $1.35B acquisition | Mark Cuban Cost Plus Drugs adds 82 drugs | Walmart loses top health exec to JPMorgan2

November 16, 2022

• 'Free insulin' tweet cost Eli Lilly billions | Oracle Cerner, Labcorp partner to manage hospital labs | Nurses slam 'immunity debt' theory for RSV | Amazon Clinic debuts | Top 25 women biotech leaders of 2022

November 09, 2022

• $2.55B life sciences hub to spur innovation, Northwell Health CEO says | Biotech co. secures $250M | Calif. hospital files for bankruptcy | Zenas BioPharma co. raises $118M

November 02, 2022

• 2,273 hospitals dinged for readmissions | JPMorgan creates life science-focused VC team | Google buys life sciences startup | CMS' 4 final payment rules: 15 notes

October 19, 2022

• Mark Cuban's pharmacy, Vivio partner | Odyssey Therapeutics secures $168M funding | Porzio Life Sciences acquired by software co. | The rise + fall of COVID billionaires

October 12, 2022

• Walmart moves into clinical trials | Rite Aid, Google create 'modern pharmacy' | JLL launches life sciences facility | Rivus Pharma raises $132M | Ro partnership aims to diversify clinical trials

October 05, 2022

• Boston, San Francisco among life science hot spots | 125 drugs in short supply: FDA | Maravai LifeSciences names William Martin CEO | Comera Life Sciences expands into Mass. lab space | Trinity sees $1.4B annual loss

September 28, 2022

• Mark Cuban partners with PBM | NexCore Group, Hatchspaces to create life science facility | Flu hits Houston Methodist hard, early | HHS to pay for 60K doses of Eli Lilly's COVID-19 drug | $14M raised by AI lung cancer diagnostics co.

September 21, 2022

• Biden to give biomanufacturing $2.8B boost | Biotech co. raises $42M | Biden edits pandemic comments | Naveris raises $33M to detect cancer caused by HPV | Ascension sees $1.8B annual loss

September 07, 2022

• Medtech co. president caught in $77M scheme | Comera Life Sciences enters purchase agreement worth $15M | COVID-19 shots expected to be annual | CVS Health to buy Signify for $8B

August 31, 2022

• 1st US monkeypox death confirmed | Life science VC firm launches $145M fund | Cleveland Clinic reports $1B loss | PDS Biotechnology Corp. completes $35M loan agreement | Biotech co. raises $5M in seed funding

August 24, 2022

• J&J business eyes bankruptcy amid talc lawsuits | Discovery Life Sciences names VP | Inflation Reduction Act: 7 healthcare notes | Common symptoms of 6 COVID variants | Cellipoint Bioservices to build Texas plant

August 17, 2022

• Merck pays $150M in biotech co. partnership | Pfizer CEO tests positive for COVID-19 | BlueJay raises $41M | Monkeypox cases by state | Boston biopharma co. completes acquisition

August 10, 2022

• Pfizer tests 1st Lyme disease vaccine candidate in 20 years | Top 100 health tech cos. | Bain invests in life sciences co. | Allscripts CEO eyes new life sciences deals | J&J's head of R&D exits